Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07006077 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Recombinant Human IL-21-expressing Oncolytic Vaccinia Virus Injection (hV01) in Advanced Pancreatic Cancer

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Feb 21, 2026 to Dec 31, 2028
    • Study completion date: Jun 5, 2026 to Mar 5, 2029
    v4
  2. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Jun 3, 2025 to May 29, 2025
    • Site details revised
    v3
  3. Study title shortened, about 5 wordsv2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The main goal of this clinical trial is to preliminary evaluate the efficacy of recombinant human IL-21-expressing oncolytic vaccinia virus injection (hV01) in patients with advanced pancreatic cancer.And the secondary purpose is to evaluate the safety of hV01.
Trial Details
NCT Number NCT07006077
Lead Sponsor Hangzhou Converd Co., Ltd.
Conditions
(from sponsor)		 Advanced Pancreatic Cancer
Related terms Pancreatic Neoplasms, Vaccinia
Enrollment 12 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov